Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection

Abstract

We report the case of a 42-year-old female patient who developed peculiar skin lesions due to subcutaneous polyethylene glycol (PEG) interferon beta-1a. The dermatological examination showed hypochromic macules that had coalesced into a 10-cm-diameter patch. On the abdomen injection sites, there was a greyish diffuse hyperpigmentation arranged irregularly in annular macules. Fungal infection, vitiligo and pityriasis alba were excluded. After 6 months, the lesions had worsened. This is the first case of localized pigmentation disorder reported with interferon beta, and while the clinical findings are not ascribable to vitiligo or interferon-related facial/mucosal hyperpigmentation, they may partially share the underlining mechanisms.

Keywords

Pegylated interferon beta-1a Plegridy injection site reaction skin lesion hypopigmented lesions

Get full access to this article

View all access options for this article.

References

Cocco

Marrosu

. Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag 2015; 11: 759–766.

Caliceti

Veronese

. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003; 55(10): 1261–1277.

Vachiramon

Thadanipon

. Postinflammatory hypopigmentation. Clin Exp Dermatol 2011; 36(7): 708–714.

Garbe

Krasagakis

. Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 1993; 100(2 Suppl): 239S–244S.

Tsilika

Tran

Trucchi

, et al. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection. JAMA Dermatol 2013; 149(6): 675–677.

Kocer

Nazliel

Oztas

, et al. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: A case report. Eur J Neurol 2009; 16(4): e78–e79.

Grimes

Bhawan

Kim

, et al. Laser resurfacing-induced hypopigmentation: Histologic alterations and repigmentation with topical photochemotherapy. Dermatol Surg 2001; 27(6): 515–520.